Belzutifan approved in Europe for advanced kidney cancer and VHL disease
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for [...]
Belzutifan plus cabozantinib combination shows promise in advanced kidney cancer
Updated results from the phase 2 LITESPARK-003 trial with belzutifan [...]
Promising new combination therapy for advanced kidney cancer
Combinations of tyrosine kinase inhibitors plus immunotherapy have improved treatment [...]
FDA approves injectable form of nivolumab
Just after Christmas, the US Food and Drug Administration (FDA) [...]
Promising new immunotherapy combination for advanced kidney cancer
The first results from a phase 2 study (FRACTION-RCC) looking [...]
New treatment for pretreated advanced kidney cancer shows promise
A new treatment, called NDI-101150 has been shown to be [...]
First CAR T-cell therapy for kidney cancer given Advanced Therapy designation by the FDA
The US Food and Drug Administration (FDA) has granted a [...]
National Kidney Cancer Audit for England and Wales
We are pleased to announce that the first ever National [...]
Belzutifan available on the NHS for patients with VHL disease
We are delighted to announce that the National Institute for [...]
Multi-million-pound UK-wide research into cancer immunotherapy
The Francis Crick Institute and The Royal Marsden NHS Foundation [...]
